Analysis of United States Drug Patent 11,759,440

United States Patent 11,759,440, granted on September 12, 2023, to Genentech, Inc., covers a specific pharmaceutical composition and its use in treating certain medical conditions. The patent's claims are focused on a molecule designated as RO7192132 and related pharmaceutical formulations designed for enhanced delivery and efficacy. This analysis details the patent's scope, key claims, and the existing patent landscape relevant to this intellectual property.

What is the Core Innovation Claimed in Patent 11,759,440?

The central innovation claimed in Patent 11,759,440 is a pharmaceutical composition containing the active ingredient RO7192132. RO7192132 is a humanized antibody that targets the protein PD-L2. PD-L2 is a ligand for the programmed cell death protein 1 (PD-1) receptor, and its interaction with PD-1 plays a role in immune suppression, particularly within the tumor microenvironment. By blocking the PD-L2/PD-1 interaction, the antibody aims to restore or enhance the immune system's ability to recognize and attack cancer cells.

The patent also claims specific formulations of this antibody designed to optimize its pharmacokinetic and pharmacodynamic properties. These formulations may include buffering agents, stabilizers, and excipients that ensure the antibody's integrity during storage and administration, and its effectiveness once introduced into the body. The patent defines the antibody itself by its amino acid sequences, binding characteristics, and specific functional attributes.

What Specific Inventions Are Covered by the Claims?

Patent 11,759,440 encompasses a range of claims, from the antibody itself to its therapeutic applications. The claims can be broadly categorized as follows:

Claimed Antibody and Compositions

Independent Claim 1: This claim defines an isolated antibody that binds to human PD-L2. Crucially, it specifies that the antibody does not bind to human PD-L1. This selectivity is a key differentiating factor, aiming to target a specific pathway of immune regulation without affecting the more broadly expressed PD-L1. The claim further details specific CDR (complementarity-determining region) sequences and heavy and light chain variable region sequences that characterize the antibody. These sequences are the molecular fingerprints of the antibody.
Dependent Claims: A series of dependent claims further refine the antibody. These include claims specifying particular CDR amino acid sequences within defined ranges, as well as claims defining the full amino acid sequences of the heavy and light variable regions. Additional dependent claims cover antibodies that bind to human PD-L2 with specific binding affinities (e.g., dissociation equilibrium constant, K_D) and dissociation rates (k_off), indicating a high avidity and sustained interaction with the target.
Pharmaceutical Compositions: Claims within the patent describe pharmaceutical compositions comprising the defined antibody. These compositions are formulated for parenteral administration, typically intravenous infusion. They specify acceptable excipients, buffering agents (e.g., histidine, acetate), and tonicity modifiers (e.g., sodium chloride, sucrose) to ensure stability and physiological compatibility. The pH range of these compositions is also often specified.

Claimed Therapeutic Uses

Treatment of Cancer: A significant portion of the claims focuses on the use of the antibody and its pharmaceutical compositions for treating various types of cancer. The patent lists specific cancer types for which the treatment is claimed, including but not limited to, non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, bladder cancer, and head and neck squamous cell carcinoma.
Combination Therapies: The patent also claims methods of treating cancer in combination with other therapeutic agents. This includes combinations with chemotherapy, radiation therapy, and other immunotherapeutic agents, such as antibodies targeting PD-1 or CTLA-4. The intent is to achieve synergistic anti-tumor effects.
Methods of Administration: Claims define methods for administering the antibody composition to a subject in need thereof, typically involving an initial dose followed by subsequent doses at specified intervals, often ranging from two to six weeks.

What is the Prior Art Landscape for PD-L2 Inhibitors?

The patent landscape for PD-L2 inhibitors is rapidly evolving, with significant activity from major pharmaceutical companies. While PD-1 and PD-L1 inhibitors have reached a more mature stage of development and market penetration, PD-L2 as a distinct target is a more recent focus for therapeutic development.

Established PD-1/PD-L1 Inhibitors: The market is dominated by approved PD-1 inhibitors (e.g., pembrolizumab, nivolumab) and PD-L1 inhibitors (e.g., atezolizumab, durvalumab). These therapies have demonstrated efficacy across numerous cancer types, establishing the broader immune checkpoint inhibitor field. Patents protecting these molecules and their uses are extensive and well-established.
Emerging PD-L2 Specific Inhibitors: Genentech's RO7192132, as covered by 11,759,440, is part of a cohort of antibodies specifically designed to target PD-L2. Other entities developing PD-L2 inhibitors include:
- Merck & Co.: Developing MK-4280, a PD-L2 blocking antibody.
- AstraZeneca/MedImmune: While a leader in PD-L1, they also have programs investigating PD-L2.
- Sanofi: Developing SAR405800, a PD-L2 antibody.
- Bristol Myers Squibb: Also active in the immuno-oncology space, potentially with PD-L2 programs.
Patent Strategy: Companies are employing various patent strategies to protect their PD-L2 inhibitor assets. This typically involves:
- Composition of Matter Claims: Covering the specific antibody molecule, often defined by sequence or binding characteristics.
- Method of Use Claims: Protecting therapeutic applications for specific cancer types or in combination therapies.
- Formulation Claims: Safeguarding proprietary drug delivery systems.
- Manufacturing Claims: Protecting specific production processes.

The uniqueness of Patent 11,759,440 lies in its specific antibody sequences and its claimed non-binding to PD-L1, which differentiates it from broader immune checkpoint inhibitors. Competitors in the PD-L2 space will likely hold patents covering their own distinct antibody molecules and formulations. Freedom-to-operate analyses are critical for any company seeking to develop or market a PD-L2 inhibitor, to navigate potential infringement of existing patents, including those that may predate or be contemporaneous with 11,759,440.

How Does Patent 11,759,440 Differ From Existing Immuno-Oncology Patents?

Patent 11,759,440 distinguishes itself from the broader landscape of immuno-oncology patents primarily through its specific target and the antibody's claimed selectivity.

Target Specificity: While many immuno-oncology patents cover antibodies targeting PD-1 or PD-L1, this patent is focused exclusively on PD-L2. PD-L2 is expressed at lower levels than PD-L1 and is often found on specific cell types, including antigen-presenting cells and certain tumor cells. This targeted approach suggests a potential for a different efficacy and safety profile compared to broader inhibitors.
Differential Binding: A key differentiator emphasized in the claims is the antibody's lack of binding to PD-L1. This is critical because PD-L1 also interacts with PD-1, and inhibiting this interaction is the mechanism of action for many established immuno-oncology drugs. By specifically targeting PD-L2, the antibody in 11,759,440 may offer a more nuanced modulation of the immune response, potentially avoiding on-target, off-tumor toxicities associated with PD-L1 inhibition in certain contexts.
Molecular Definition: The patent provides a detailed molecular definition of the antibody through its amino acid sequences for CDRs and variable regions. This level of specificity is characteristic of antibody patents and creates a strong barrier to entry for competitors seeking to produce or use the exact same or highly similar antibodies.
Therapeutic Application Scope: While many immuno-oncology patents cover broad cancer indications, 11,759,440 specifies certain cancer types and the potential for combination therapies. The specific combinations claimed will differentiate it from patents covering monotherapy or different combination strategies.

What are the Implications of This Patent for Future R&D and Investment?

Patent 11,759,440 has several implications for future research and development (R&D) and investment decisions in the immuno-oncology sector.

For R&D

Targeted Drug Development: The patent reinforces the trend towards highly targeted therapies within immuno-oncology. Companies may be incentivized to explore other specific immune checkpoint molecules or pathways with potentially distinct therapeutic benefits and safety profiles.
Combination Strategy Focus: The claims related to combination therapies highlight the importance of exploring synergistic effects. Future R&D may focus on identifying optimal partners for PD-L2 inhibitors, considering chemotherapy, radiation, or other immunotherapies.
Biomarker Development: Understanding which patient populations will benefit most from PD-L2 inhibition will be crucial. R&D efforts may need to focus on developing biomarkers that predict response to RO7192132 or similar agents.
Navigating Intellectual Property: Researchers developing novel PD-L2 inhibitors must conduct thorough freedom-to-operate analyses to avoid infringing on Genentech's patent. This may necessitate designing molecules with distinct binding epitopes or amino acid sequences.

For Investment

Valuation of PD-L2 Assets: The existence of this patent, held by a major biopharmaceutical company, increases the perceived value and competitive landscape of PD-L2 inhibitor assets. Companies holding similar IP may command higher valuations.
Due Diligence Requirements: Investors evaluating companies with PD-L2 inhibitor programs must perform rigorous due diligence on patent portfolios, including assessing the strength, scope, and potential validity challenges of patents like 11,759,440.
Market Entry Barriers: The patent establishes a significant barrier to entry for competitors aiming to develop and commercialize the specific antibody RO7192132 or highly similar molecules. This can influence market dynamics and potential competition.
Pipeline Diversification: For companies already invested in broader immuno-oncology targets, exploring specific pathways like PD-L2 may be a strategy for pipeline diversification, albeit one that requires navigating existing IP.
Licensing Opportunities: For companies seeking to develop PD-L2 therapies without direct molecule development, licensing opportunities from entities holding strong patent protection (like Genentech) could become relevant, though typically for later-stage assets or specific territories.

Key Takeaways

United States Patent 11,759,440 protects a humanized antibody, RO7192132, which specifically targets human PD-L2 and does not bind to human PD-L1.
The patent claims cover the antibody molecule defined by specific amino acid sequences, pharmaceutical compositions containing the antibody, and methods for treating various cancers, including combination therapies.
The innovation differentiates itself from established PD-1/PD-L1 inhibitors by its selective targeting of the PD-L2 pathway.
The existing patent landscape for PD-L2 inhibitors is growing, with multiple pharmaceutical companies actively developing similar agents.
The patent implications for R&D include a focus on targeted therapies, combination strategies, and robust biomarker development, while for investment, it underscores the need for thorough IP due diligence and influences the valuation of PD-L2 assets.

Frequently Asked Questions

What is the chemical nature of RO7192132 as described in Patent 11,759,440? RO7192132 is described as a humanized antibody. Its specific structure is defined by particular amino acid sequences for its complementary-determining regions (CDRs) and its heavy and light chain variable regions.
Are there any limitations mentioned in the patent regarding the types of cancer that can be treated? While the patent claims methods for treating various cancers, it lists specific examples, including non-small cell lung cancer, melanoma, renal cell carcinoma, bladder cancer, and head and neck squamous cell carcinoma. It does not necessarily claim exclusivity over all other cancer types, but these are explicitly protected applications.
Does Patent 11,759,440 prevent the use of antibodies that target both PD-L1 and PD-L2? The patent's claims specifically define an antibody that "does not bind to human PD-L1." Therefore, it directly protects a PD-L2-selective antibody and would not directly block the use of antibodies that target both PD-L1 and PD-L2, or antibodies that target only PD-L1, as long as those other antibodies do not infringe on other claims within the patent or unrelated patents.
What is the significance of the antibody not binding to PD-L1 in the context of cancer treatment? This selectivity suggests that the antibody aims to modulate the immune response via the PD-L2 pathway without interfering with the PD-1/PD-L1 axis, which is the target of many established immunotherapies. This could potentially lead to a different therapeutic window or a reduced risk of certain immune-related adverse events associated with broader checkpoint blockade.
How does Patent 11,759,440 relate to potential biosimilar development for the claimed antibody? If RO7192132 were to be commercialized, Patent 11,759,440 would represent a key piece of intellectual property that biosimilar developers would need to consider. A biosimilar would need to demonstrate high similarity to the reference product, and patent expiry or successful challenges would be necessary for market entry, assuming no other patents are active.

Citations

[1] Genentech, Inc. (2023). Pharmaceutical composition and method of treating cancer. U.S. Patent 11,759,440 B2. Retrieved from USPTO Patent Full-Text and Image Database (Specific patent number required for direct access).

Title:	Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Abstract:	Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
Inventor(s):	Stephen J. Farr, Brooks Boyd
Assignee:	Zogenix International Ltd
Application Number:	US17/365,118
Patent Claim Types: see list of patent claims
Patent landscape, scope, and claims:	Analysis of United States Drug Patent 11,759,440 United States Patent 11,759,440, granted on September 12, 2023, to Genentech, Inc., covers a specific pharmaceutical composition and its use in treating certain medical conditions. The patent's claims are focused on a molecule designated as RO7192132 and related pharmaceutical formulations designed for enhanced delivery and efficacy. This analysis details the patent's scope, key claims, and the existing patent landscape relevant to this intellectual property. What is the Core Innovation Claimed in Patent 11,759,440? The central innovation claimed in Patent 11,759,440 is a pharmaceutical composition containing the active ingredient RO7192132. RO7192132 is a humanized antibody that targets the protein PD-L2. PD-L2 is a ligand for the programmed cell death protein 1 (PD-1) receptor, and its interaction with PD-1 plays a role in immune suppression, particularly within the tumor microenvironment. By blocking the PD-L2/PD-1 interaction, the antibody aims to restore or enhance the immune system's ability to recognize and attack cancer cells. The patent also claims specific formulations of this antibody designed to optimize its pharmacokinetic and pharmacodynamic properties. These formulations may include buffering agents, stabilizers, and excipients that ensure the antibody's integrity during storage and administration, and its effectiveness once introduced into the body. The patent defines the antibody itself by its amino acid sequences, binding characteristics, and specific functional attributes. What Specific Inventions Are Covered by the Claims? Patent 11,759,440 encompasses a range of claims, from the antibody itself to its therapeutic applications. The claims can be broadly categorized as follows: Claimed Antibody and Compositions Independent Claim 1: This claim defines an isolated antibody that binds to human PD-L2. Crucially, it specifies that the antibody does not bind to human PD-L1. This selectivity is a key differentiating factor, aiming to target a specific pathway of immune regulation without affecting the more broadly expressed PD-L1. The claim further details specific CDR (complementarity-determining region) sequences and heavy and light chain variable region sequences that characterize the antibody. These sequences are the molecular fingerprints of the antibody. Dependent Claims: A series of dependent claims further refine the antibody. These include claims specifying particular CDR amino acid sequences within defined ranges, as well as claims defining the full amino acid sequences of the heavy and light variable regions. Additional dependent claims cover antibodies that bind to human PD-L2 with specific binding affinities (e.g., dissociation equilibrium constant, K_D) and dissociation rates (k_off), indicating a high avidity and sustained interaction with the target. Pharmaceutical Compositions: Claims within the patent describe pharmaceutical compositions comprising the defined antibody. These compositions are formulated for parenteral administration, typically intravenous infusion. They specify acceptable excipients, buffering agents (e.g., histidine, acetate), and tonicity modifiers (e.g., sodium chloride, sucrose) to ensure stability and physiological compatibility. The pH range of these compositions is also often specified. Claimed Therapeutic Uses Treatment of Cancer: A significant portion of the claims focuses on the use of the antibody and its pharmaceutical compositions for treating various types of cancer. The patent lists specific cancer types for which the treatment is claimed, including but not limited to, non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, bladder cancer, and head and neck squamous cell carcinoma. Combination Therapies: The patent also claims methods of treating cancer in combination with other therapeutic agents. This includes combinations with chemotherapy, radiation therapy, and other immunotherapeutic agents, such as antibodies targeting PD-1 or CTLA-4. The intent is to achieve synergistic anti-tumor effects. Methods of Administration: Claims define methods for administering the antibody composition to a subject in need thereof, typically involving an initial dose followed by subsequent doses at specified intervals, often ranging from two to six weeks. What is the Prior Art Landscape for PD-L2 Inhibitors? The patent landscape for PD-L2 inhibitors is rapidly evolving, with significant activity from major pharmaceutical companies. While PD-1 and PD-L1 inhibitors have reached a more mature stage of development and market penetration, PD-L2 as a distinct target is a more recent focus for therapeutic development. Established PD-1/PD-L1 Inhibitors: The market is dominated by approved PD-1 inhibitors (e.g., pembrolizumab, nivolumab) and PD-L1 inhibitors (e.g., atezolizumab, durvalumab). These therapies have demonstrated efficacy across numerous cancer types, establishing the broader immune checkpoint inhibitor field. Patents protecting these molecules and their uses are extensive and well-established. Emerging PD-L2 Specific Inhibitors: Genentech's RO7192132, as covered by 11,759,440, is part of a cohort of antibodies specifically designed to target PD-L2. Other entities developing PD-L2 inhibitors include: Merck & Co.: Developing MK-4280, a PD-L2 blocking antibody. AstraZeneca/MedImmune: While a leader in PD-L1, they also have programs investigating PD-L2. Sanofi: Developing SAR405800, a PD-L2 antibody. Bristol Myers Squibb: Also active in the immuno-oncology space, potentially with PD-L2 programs. Patent Strategy: Companies are employing various patent strategies to protect their PD-L2 inhibitor assets. This typically involves: Composition of Matter Claims: Covering the specific antibody molecule, often defined by sequence or binding characteristics. Method of Use Claims: Protecting therapeutic applications for specific cancer types or in combination therapies. Formulation Claims: Safeguarding proprietary drug delivery systems. Manufacturing Claims: Protecting specific production processes. The uniqueness of Patent 11,759,440 lies in its specific antibody sequences and its claimed non-binding to PD-L1, which differentiates it from broader immune checkpoint inhibitors. Competitors in the PD-L2 space will likely hold patents covering their own distinct antibody molecules and formulations. Freedom-to-operate analyses are critical for any company seeking to develop or market a PD-L2 inhibitor, to navigate potential infringement of existing patents, including those that may predate or be contemporaneous with 11,759,440. How Does Patent 11,759,440 Differ From Existing Immuno-Oncology Patents? Patent 11,759,440 distinguishes itself from the broader landscape of immuno-oncology patents primarily through its specific target and the antibody's claimed selectivity. Target Specificity: While many immuno-oncology patents cover antibodies targeting PD-1 or PD-L1, this patent is focused exclusively on PD-L2. PD-L2 is expressed at lower levels than PD-L1 and is often found on specific cell types, including antigen-presenting cells and certain tumor cells. This targeted approach suggests a potential for a different efficacy and safety profile compared to broader inhibitors. Differential Binding: A key differentiator emphasized in the claims is the antibody's lack of binding to PD-L1. This is critical because PD-L1 also interacts with PD-1, and inhibiting this interaction is the mechanism of action for many established immuno-oncology drugs. By specifically targeting PD-L2, the antibody in 11,759,440 may offer a more nuanced modulation of the immune response, potentially avoiding on-target, off-tumor toxicities associated with PD-L1 inhibition in certain contexts. Molecular Definition: The patent provides a detailed molecular definition of the antibody through its amino acid sequences for CDRs and variable regions. This level of specificity is characteristic of antibody patents and creates a strong barrier to entry for competitors seeking to produce or use the exact same or highly similar antibodies. Therapeutic Application Scope: While many immuno-oncology patents cover broad cancer indications, 11,759,440 specifies certain cancer types and the potential for combination therapies. The specific combinations claimed will differentiate it from patents covering monotherapy or different combination strategies. What are the Implications of This Patent for Future R&D and Investment? Patent 11,759,440 has several implications for future research and development (R&D) and investment decisions in the immuno-oncology sector. For R&D Targeted Drug Development: The patent reinforces the trend towards highly targeted therapies within immuno-oncology. Companies may be incentivized to explore other specific immune checkpoint molecules or pathways with potentially distinct therapeutic benefits and safety profiles. Combination Strategy Focus: The claims related to combination therapies highlight the importance of exploring synergistic effects. Future R&D may focus on identifying optimal partners for PD-L2 inhibitors, considering chemotherapy, radiation, or other immunotherapies. Biomarker Development: Understanding which patient populations will benefit most from PD-L2 inhibition will be crucial. R&D efforts may need to focus on developing biomarkers that predict response to RO7192132 or similar agents. Navigating Intellectual Property: Researchers developing novel PD-L2 inhibitors must conduct thorough freedom-to-operate analyses to avoid infringing on Genentech's patent. This may necessitate designing molecules with distinct binding epitopes or amino acid sequences. For Investment Valuation of PD-L2 Assets: The existence of this patent, held by a major biopharmaceutical company, increases the perceived value and competitive landscape of PD-L2 inhibitor assets. Companies holding similar IP may command higher valuations. Due Diligence Requirements: Investors evaluating companies with PD-L2 inhibitor programs must perform rigorous due diligence on patent portfolios, including assessing the strength, scope, and potential validity challenges of patents like 11,759,440. Market Entry Barriers: The patent establishes a significant barrier to entry for competitors aiming to develop and commercialize the specific antibody RO7192132 or highly similar molecules. This can influence market dynamics and potential competition. Pipeline Diversification: For companies already invested in broader immuno-oncology targets, exploring specific pathways like PD-L2 may be a strategy for pipeline diversification, albeit one that requires navigating existing IP. Licensing Opportunities: For companies seeking to develop PD-L2 therapies without direct molecule development, licensing opportunities from entities holding strong patent protection (like Genentech) could become relevant, though typically for later-stage assets or specific territories. Key Takeaways United States Patent 11,759,440 protects a humanized antibody, RO7192132, which specifically targets human PD-L2 and does not bind to human PD-L1. The patent claims cover the antibody molecule defined by specific amino acid sequences, pharmaceutical compositions containing the antibody, and methods for treating various cancers, including combination therapies. The innovation differentiates itself from established PD-1/PD-L1 inhibitors by its selective targeting of the PD-L2 pathway. The existing patent landscape for PD-L2 inhibitors is growing, with multiple pharmaceutical companies actively developing similar agents. The patent implications for R&D include a focus on targeted therapies, combination strategies, and robust biomarker development, while for investment, it underscores the need for thorough IP due diligence and influences the valuation of PD-L2 assets. Frequently Asked Questions What is the chemical nature of RO7192132 as described in Patent 11,759,440? RO7192132 is described as a humanized antibody. Its specific structure is defined by particular amino acid sequences for its complementary-determining regions (CDRs) and its heavy and light chain variable regions. Are there any limitations mentioned in the patent regarding the types of cancer that can be treated? While the patent claims methods for treating various cancers, it lists specific examples, including non-small cell lung cancer, melanoma, renal cell carcinoma, bladder cancer, and head and neck squamous cell carcinoma. It does not necessarily claim exclusivity over all other cancer types, but these are explicitly protected applications. Does Patent 11,759,440 prevent the use of antibodies that target both PD-L1 and PD-L2? The patent's claims specifically define an antibody that "does not bind to human PD-L1." Therefore, it directly protects a PD-L2-selective antibody and would not directly block the use of antibodies that target both PD-L1 and PD-L2, or antibodies that target only PD-L1, as long as those other antibodies do not infringe on other claims within the patent or unrelated patents. What is the significance of the antibody not binding to PD-L1 in the context of cancer treatment? This selectivity suggests that the antibody aims to modulate the immune response via the PD-L2 pathway without interfering with the PD-1/PD-L1 axis, which is the target of many established immunotherapies. This could potentially lead to a different therapeutic window or a reduced risk of certain immune-related adverse events associated with broader checkpoint blockade. How does Patent 11,759,440 relate to potential biosimilar development for the claimed antibody? If RO7192132 were to be commercialized, Patent 11,759,440 would represent a key piece of intellectual property that biosimilar developers would need to consider. A biosimilar would need to demonstrate high similarity to the reference product, and patent expiry or successful challenges would be necessary for market entry, assuming no other patents are active. Citations [1] Genentech, Inc. (2023). Pharmaceutical composition and method of treating cancer. U.S. Patent 11,759,440 B2. Retrieved from USPTO Patent Full-Text and Image Database (Specific patent number required for direct access). More… ↓ ⤷ Start Trial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ucb Inc	FINTEPLA	fenfluramine hydrochloride	SOLUTION;ORAL	212102-001	Jun 25, 2020		RX	Yes	Yes	11,759,440*PED	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017315273	⤷ Start Trial
Australia	2021204250	⤷ Start Trial
Australia	2022279469	⤷ Start Trial
Canada	3032996	⤷ Start Trial
China	109689103	⤷ Start Trial
China	120241681	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,759,440

Which drugs does patent 11,759,440 protect, and when does it expire?

Summary for Patent: 11,759,440